Cytophage Announces Formation of Special Committee of Independent Directors to Evaluate Strategic Alternatives

Executive Summary

• Cytophage Technologies’ Board has created an independent Special Committee to evaluate unsolicited strategic financing proposals and explore all strategic alternatives, including a possible merger, sale, or other business combination.
• No timetable or decision has been set; the Company will not provide further updates until material information is available or required by law.

Key Details

• The Special Committee is composed solely of independent and disinterested directors.
• The Committee’s mandate includes overseeing a competitive process for due diligence and negotiating a firm, final financing offer if one materializes.
• The Company is currently receiving unsolicited strategic financing proposals.
• Potential alternatives under consideration: merger, sale, or other business combination.
• No commitments have been made; the Board has not established a timeline for any transaction.
• Cytophage will refrain from further commentary on the process unless additional disclosure becomes appropriate or legally required.

Notable Quotes

(No direct quotes were provided in the release.)